A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result

We aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months. Sixty eyes from 56 patients receiving brolucizumab for exudative AMD refractor...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Wataru Kikushima, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Yumi Kotoda, Atsushi Sugiyama, Kenji Kashiwagi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2023-04-01
coleção:	Pharmaceuticals
Assuntos:	age-related macular degeneration polypoidal choroidal vasculopathy intravitreal brolucizumab injection treat-and-extend switching
Acesso em linha:	https://www.mdpi.com/1424-8247/16/4/562
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!